Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retinoids in cutaneous T cell lymphomas.

G Mahrle1, B Thiele

  • 1Universitäts-Hautklinik, Köln, FRG.

Dermatologica
|January 1, 1987
PubMed
Summary

New retinoid treatments, including a potent arotinoid and Re-PUVA (etretinate and PUVA therapy), showed significant skin lesion response in patients with cutaneous T cell lymphoma (CTCL) and related conditions. Relapses occurred after treatment cessation, indicating the need for ongoing management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutational landscape reflects the biological continuum of plasma cell dyscrasias.

Blood cancer journal·2017
Same author

Evidence for the founder effect of a novel ACVRL1 splice-site mutation in Hungarian hereditary hemorrhagic telangiectasia families.

Clinical genetics·2016
Same author

[In honor of Professor Dr. Dr. h.c. G. K. Steigleder on the occasion of his 90th birthday].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2015
Same author

Vasoactive-intestinal-Peptide (vip) modulates the growth fraction of epithelial skin cells.

International journal of oncology·2011
Same author

A multi-site study using high-resolution HLA genotyping by next generation sequencing.

Tissue antigens·2011
Same author

Donor cell-derived myelodysplastic syndrome in a patient 7 years after unrelated allogeneic HLA-mismatched transplantation for Ph+ chronic myeloid leukemia.

Bone marrow transplantation·2005

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Cutaneous T cell lymphoma (CTCL) and related disorders present significant treatment challenges.
  • Retinoids and phototherapy (PUVA) are established treatments for these conditions.
  • Novel arotinoid compounds offer potential new therapeutic avenues.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of a new potent arotinoid, alone or in combination with etretinate and PUVA (Re-PUVA), for CTCL and related skin conditions.
  • To compare the therapeutic outcomes of arotinoid monotherapy versus the Re-PUVA regimen.

Main Methods:

  • Sixteen patients with CTCL, Sézary syndrome, actinic reticuloid, or parapsoriasis variegata were enrolled.
  • Treatment involved either a potent arotinoid or combined etretinate (Tigason) and PUVA therapy (Re-PUVA).
  • Patient response, lesion clearance, and toxicity were monitored.

Main Results:

  • 92% of patients demonstrated a minor to distinct response in skin lesions within an average of 12.6 weeks.
  • Over 67% of patients achieved more than 50% clearance of skin lesions.
  • No significant difference in therapeutic efficacy was observed between the arotinoid alone and Re-PUVA groups.
  • The Re-PUVA regimen exhibited lower toxicity compared to arotinoid monotherapy.
  • Relapses occurred in all patients within 3-10 weeks after discontinuing retinoid therapy.

Conclusions:

  • Both a potent arotinoid and the Re-PUVA regimen are effective in treating skin lesions associated with CTCL and related conditions.
  • Re-PUVA may offer a less toxic alternative with comparable efficacy to arotinoid monotherapy.
  • The high rate of relapse post-treatment cessation highlights the chronic nature of these diseases and the potential need for maintenance therapy.

Related Experiment Videos